Pink October

4 Oct 2021 | News

Cancer is the second deadliest disease in the world.

In the ART-field many of the patients need help due to a cancer diagnosis or the symptoms of the treatments or the disease itself.We want to support and bring awareness to this group. We therefore made a limited edition of our Nidacon hat and buff in a really bright and pink colour to remind us all and bring awareness.

We will donate to the cancer organisation which supports the research on cancer and the development of new treatments.

We will wear these pink garments with pride and hope that you will join us!

Other news from the Nidacon world

ESHRE 40th Annual Meeting

17 Jun 2024

We're excited to be at ESHRE again this year, just like every year! Come and visit us at stand 12076. This year, we’re thrilled to introduce our new Japanese partner, Varinos, and their innovative endometrial microbiome test. We can't wait to see you there!

Nidacon will be closed over Easter

22 Mar 2024

The Nidacon office will be closed between March 29th and April 1st. We will open again on the 2nd of April. Wish You a happy Easter! /The Nidacon Team

Our workshop was a resounding success!

9 Feb 2024

We examined different methods and products for sperm preparation. We know that proper handling of sperm significantly increases the chances of fertilization, thanks to the embryologists who attended our workshop, representing various clinics in Sweden. Nidacon...

Is transportation without cold chain safe?

16 Jan 2024

Concerns may arise regarding the effect of extreme weather conditions on product performance. To address these concerns, all Nidacon products undergo rigorous testing for elevated temperatures up to 50°C and down to -18°C over a span of 5 days. The results of these...

Doctors Without Borders

4 Dec 2023

This year we have made the choice to contribute to life saving health care through Doctors Without Borders (MSF), who over the past year have conducted 3 million routine vaccinations, assisted in over 300,000 childbirths, and performed more than 12.5 million patient...